Paxlovid helps prevent #PERSISTENTCOVID and reduces hospitalization of older adults by 85%. But the pharmaceutical company does not allow the distribution of generics. Let us save lives! Sign the petition for Latin America to have access to this drug.

December 12th, 2022

We, NGO Innovarte (Chile) and AIS (Peru) and other non-profit organizations, demand Pfizer to stop the monopoly on the drug PAXLOVID and allow the distribution of generics throughout Latin America.

This treatment reduces the risk of hospitalizations in older adults by 85% and helps to overcome Persistent Covid. However, it is not available unless it is imported by paying hundreds of dollars. 

In April, the World Health Organization (WHO) recommended the use of PAXLOVID™ in patients at high risk of hospital admission; and described it as the best therapeutic option to date for at-risk population and older adults.

The health emergency makes urgent the accelerated access to Paxlovid, in adequate quantity and conditions. Therefore, Pfizer must include, for ethical and public health reasons, all Latin American countries among those authorized to access generics manufactured in neighboring countries.

Let us remember that the Pandemic will not end if it is not controlled worldwide and that we are still far from a solidary distribution of all the tools available to fight it.  This letter positively urges Pfizer to include all Latin American countries among those authorized to purchase generic Paxlovid treatments, and thus avoid hospitalizations and deaths due to the monopoly.

Help us save lives by signing and sharing our campaign!